ClinicalTrials.gg
CompletedNCT04101968Updated Sep 2, 2026

The GBA Multimodal Study in Parkinson's Disease

An observational study in Parkinson Disease, GBA Gene Mutation and Gaucher Disease, sponsored by Pacific Parkinson's Research Centre. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Pacific Parkinson's Research Centre · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
30
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.

Enrollment
278th of 379
30 · median 78
Started
2019
with 104 others
Observational
381 of 1,650
75 open now
Registered
1,000th of 1,650
by date

Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 278th largest by enrollment of the 379 observational ones that give a count, is one of 105 that started in 2019, is one of 381 observational ones, and was the 1,000th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

300 more — sign in →

All 305 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,650 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.

Read the detailed description

Study Rationale: People who have a mutation in the GBA gene have a higher risk of developing Parkinson's disease (PD) and, if they have PD, are more likely to have cognitive decline and dementia. Cognitive problems in people with PD is related to dysfunction of the brain chemical acetylcholine and likely to the accumulation of the tau protein in the brain. Another observation in previous studies is that analyzing the patterns of typing into a computer can help differentiate healthy people from people with PD.

Hypothesis: The investigators hypothesize that people with GBA-related PD will have higher acetylcholine dysfunction and tau accumulation compared with non-GBA patients, and that these changes may start in the asymptomatic phase (i.e., people with the mutation but without symptoms of PD). The investigators also believe that the investigators will be able to detect subjects with higher degree of dopamine loss just by analyzing the way they type into a computer.

Study Design: The investigators will recruit 25 subjects with a GBA mutation (10 subjects with PD and 15 asymptomatic carriers). All the participants will have a clinical evaluation and a typing session, and subsequently will undergo a brain MRI and three PET scans with a tau tracer, an acetylcholine tracer, and a dopaminergic tracer. A blood sample will also be taken for the analysis of GCase (the enzyme related to the GBA mutation).

Impact on Diagnosis/Treatment of Parkinson's Disease: The results will help understand the changes that take place in the brain of people with GBA-related Parkinson's disease, and hopefully will shed light also on the pathophysiology of non-GBA-related Parkinson's, as well as on the molecular correlates of cognitive decline, especially in its early stage. The typing data along with dopaminergic imaging will clarify the possible role of using typing patterns to identify subjects with early stage Parkinson's disease.

Next Steps for Development: The findings of this study may help identify biomarkers for cognitive decline in early Parkinson's disease, with a potential role in clinical trials. Also, if the hypothesis on the typing is confirmed, this approach may be studied in larger cohorts for early diagnosis of Parkinson's in other at-risk populations.

03

Conditions studied

  • Parkinson Disease
  • GBA Gene Mutation
  • Gaucher Disease

Keywords

  • Parkinson
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

People with a known pathogenic GBA gene mutation with or without PD.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • heterozygous for a pathogenic GBA mutation (e.g., p.L444P, p.N370S) or polymorphism;
  • age 18 to 80 years.

Exclusion criteria

Exclusion Criteria:

  • co-occurrence of other neurological disorders;
  • implants that contraindicate the MRI scanning (e.g. cardiac pacemaker, ferromagnetic implants or devices);
  • severe claustrophobia;
  • intolerance to antiparkinsonian drug withdrawal (for GBA-PD subjects);
  • ongoing treatment with cholinergic drugs
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
30 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • GBA-PD

    People with Parkinson's disease who are known heterozygous carriers of pathogenic GBA gene mutations.

    Diagnostic Test: PET scan · Diagnostic Test: neuroQWERTY

  • Asymptomatic GBA

    Known heterozygous carriers/obligated carriers of pathogenic GBA gene mutations.

    Diagnostic Test: PET scan · Diagnostic Test: neuroQWERTY

Interventions

  • Diagnostic testPET scan

    3 PET scans to analyze the dopamine metabolism, acetylcholine and tau protein deposition in the brain.

  • Diagnostic testneuroQWERTY

    Analysis of free-text typing in a computer and/or a touch-screen device.

06

What researchers measure

Primary outcomes

  1. Acetylcholinesterase activity

    11C-PMP PET

    Time frame: baseline

  2. Tau protein deposition

    11C-PBB3 PET

    Time frame: baseline

  3. Dopaminergic denervation

    11C-DTBZ PET

    Time frame: baseline

  4. neuroQWERTY index

    Typing analysis

    Time frame: baseline

07

Study locations

3 sites
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • University of Washington
    Seattle, Washington 98108-1595, United States
  • Pacific Parkinson's Research Centre | University of British Columbia
    Vancouver, British Columbia, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Jun 2026, 85 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2019
First posted
Sep 24, 2019
StartActual
May 1, 2019
Primary completionActual
Jun 30, 2026
CompletionActual
Jun 30, 2026
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04101968
Lead sponsor
Pacific Parkinson's Research Centre
Collaborators
University of British Columbia, University of Washington, Oregon Health and Science University, Simon Fraser University, Michael J. Fox Foundation for Parkinson's Research, Silverstein Foundation, Weston Brain Institute
Responsible party
Sponsor
First posted
Sep 24, 2019
Start date
May 1, 2019
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026
Last update
Sep 2, 2026

Study contacts

Michele Matarazzo, MD
principal investigator · Pacific Parkinson's Research Centre | University of British Columbia
A. Jon Stoessl, CM, MD, FRCPC, FCAHS
principal investigator · Pacific Parkinson's Research Centre | University of British Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion